WO2012014149A1 - N-methylformamide solvate of dasatinib - Google Patents

N-methylformamide solvate of dasatinib Download PDF

Info

Publication number
WO2012014149A1
WO2012014149A1 PCT/IB2011/053318 IB2011053318W WO2012014149A1 WO 2012014149 A1 WO2012014149 A1 WO 2012014149A1 IB 2011053318 W IB2011053318 W IB 2011053318W WO 2012014149 A1 WO2012014149 A1 WO 2012014149A1
Authority
WO
WIPO (PCT)
Prior art keywords
dasatinib
solvate
methylformamide
crystalline
methylformamide solvate
Prior art date
Application number
PCT/IB2011/053318
Other languages
French (fr)
Inventor
Jagdev Singh Jaryal
Sudhir Singh Sanwal
Saridi Madhava Dileep Kumar
Swargam Sathyanarayana
Rajesh Kumar Thaper
Mohan Prasad
Sudershan Kumar Arora
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Priority to CA2806820A priority Critical patent/CA2806820A1/en
Priority to AU2011284341A priority patent/AU2011284341A1/en
Priority to EP11751946.2A priority patent/EP2598147A1/en
Publication of WO2012014149A1 publication Critical patent/WO2012014149A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a N-Methylformamide solvate of dasatinib and a process for its preparation.
  • Dasatinib monohydrate of Formula A is a cyclic protein tyrosine kinase inhibitor.
  • Dasatinib monohydrate marketed under the brand name Sprycel®, is indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.
  • Sprycel® is also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
  • U.S. Patent No. 6,596,746 provides a process for the preparation of dasatinib.
  • U.S. Patent No. 7,491,725 provides for the crystalline monohydrate, butanol solvate form, crystalline ethanol solvates and neat forms of dasatinib. It also provides a process for the preparation of crystalline monohydrate, butanol solvate form, crystalline ethanol solvate and neat form of dasatinib.
  • U.S. Publication No. 2009/0118297 provides for the anhydrous form, amorphous form, iso-propanol solvate, a n-propanol-dimethylsulfoxide (“DMSO”) solvate, a DMSO solvate, a hemi tetrahydrofuran (“THF”) solvate, a 2-methyl-tetrahydrofuran (“2-methyl THF”) solvate, a hemi 1,4-dioxane solvate, a pyridine solvate, a toluene solvate, a methyl isobutyl ketone (“MIBK”) solvate, a mono acetone solvate, an iso-propanol (“IPA”)- DMSO solvate, a 2-butanol-DMSO solvate, an IPA-DMF solvate, an IPA solvate, an n- propanol-DMF solvate, an n-
  • dimethoxyethane solvate dimethoxyethane solvate, a methylethylketone (“MEK”) solvate, a monochlorobenzene solvate, a propylene glycol monoethyl ether (“PGME”) solvate, a glycerol solvate, a cyclopentyl methyl ether solvate, a methyl tert butyl ether (“MTBE”) solvate, an amylalcohol solvate, a glycerol formal solvate of dasatinib and processes for their preparation.
  • MEK methylethylketone
  • PGME propylene glycol monoethyl ether
  • glycerol solvate glycerol solvate
  • MTBE methyl tert butyl ether
  • amylalcohol solvate a glycerol formal solvate of dasatinib and processes for their preparation.
  • WO 2010/062715 discloses an isosorbide dimethyl ether solvate of dasatinib, a ⁇ , ⁇ '-dimethylethylene urea solvate of dasatinib, and a N,N'-dimethyl-N,N'-propylene urea solvate of dasatinib and processes for their preparation.
  • WO 2010/067374 discloses a dimethylformamide solvate, dimethyl sulfoxide solvate, toluene solvate, isopropyl acetate solvate, crystalline Form I of dasatinib characterized by their X-ray powder diffractogram and processes for their preparation.
  • Polymorphism is defined as the ability of a substance to exist as two or more crystalline phases that have different arrangements and/or conformations of the molecule in the crystal lattice. Different polymorphs may differ in their physical properties, such as, melting point, solubility, X-ray diffraction patterns, and the like.
  • Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray Diffraction (XRD) powder as well as single crystal, DSC, IR, Solid state NMR, or Raman spectroscopy.
  • XRD X-ray Diffraction
  • the present inventors have now surprisingly found a N-Methylformamide solvate of dasatinib.
  • the novel N-Methylformamide solvate of dasatinib of the present invention is suitable for preparing pharmaceutical compositions.
  • the present invention provides for N-Methylformamide solvate of dasatinib of Formula B.
  • the present invention provides for crystalline N- Methylformamide solvate of dasatinib characterized by an X-Ray Powder Diffractogram (XRPD) substantially as depicted in Figure 1.
  • XRPD X-Ray Powder Diffractogram
  • the present invention provides for crystalline N- Methylformamide solvate of dasatinib characterized by an X-ray Powder Diffractogram which includes interplanar distances at approximately 14.21 , 7.1 1 , 5.80, 4.74, and 3.65 A.
  • Embodiments of this aspect may include one or more of the following features.
  • the crystalline N-Methylformamide solvate of dasatinib may be further characterized by an X-ray Powder Diffractogram which includes interplanar distance at approximately 7.45, 4.83, 4.29, 3.82, 3.73 and 3.49 A.
  • the crystalline N-Methylformamide solvate of dasatinib may further be characterized by a DSC thermogram substantially as depicted in Figure 2.
  • the crystalline N-Methylformamide solvate of dasatinib may have characteristic DSC endothermic peaks at about 160°C and about 287°C.
  • the crystalline N-Methylformamide solvate of dasatinib may also be further characterized by a TGA substantially as depicted in Figure 3.
  • the present invention provides for a process for the preparation of N-Methylformamide solvate of dasatinib.
  • the process includes:
  • Embodiments of this aspect may include one or more of the following features.
  • step a) is carried out at a temperature of 20°C to 50°C and the amount of N- Methylformamide is 3 to 10 times the amount of dasatinib.
  • the present invention provides for the use of N- Methylformamide solvate of dasatinib for the preparation of other polymorphic forms or solvates of dasatinib.
  • the present invention provides for a pharmaceutical composition which includes a therapeutically effective amount of N-Methylformamide solvate of dasatinib and one or more pharmaceutically acceptable excipients.
  • the present invention provides for a method for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute
  • the method includes administering to a mammal in need thereof a therapeutically effective amount of N-Methylformamide solvate of dasatinib.
  • Figure 1 and Figure la depicts X-Ray Powder Diffractogram (XRPD) of N- Methylformamide solvate of dasatinib and the associated values, respectively.
  • XRPD X-Ray Powder Diffractogram
  • FIG. 2 depicts Differential Scanning Calorimetry (DSC) thermogram of N- Methylformamide solvate of dasatinib.
  • Figure 3 depicts Thermogravimetric Analysis (TGA) of N-Methylformamide solvate of dasatinib.
  • the XRPD was determined by using PANalytical X' Pert Pro X-Ray Powder Diffractometer in the range 0°C to 40°C 2 ⁇ and under tube voltage and current of 45 Kv and 40 mA, respectively. Copper radiation of wavelength 1.54 angstrom and Xceletor detector was used.
  • the present invention provides for the N-Methylformamide solvate of dasatinib of Formula B
  • the present invention may be in the form of crystalline N-Methylformamide solvate of dasatinib.
  • the crystalline N-Methylformamide solvate of dasatinib has an X-Ray Powder Diffractogram (XRPD) substantially as depicted in Figure 1 of the accompanied drawings.
  • the crystalline N-Methylformamide solvate of dasatinib has an X-ray Powder Diffractogram which shows characteristic peaks expressed as interplanar distance at approximately 14.21, 7.11, 5.80, 4.74, and 3.65 A.
  • the crystalline N- Methylformamide solvate of dasatinib may be further characterized by peaks expressed as interplanar distance at approximately 7.45, 4.83, 4.29, 3.82, 3.73 and 3.49 A.
  • the crystalline N-Methylformamide solvate of dasatinib has a DSC thermogram substantially as depicted in Figure 2 of the accompanied drawings.
  • the DSC thermogram shows characteristic endothermic peaks at about 160°C and about 287°C.
  • the crystalline N-Methylformamide solvate of dasatinib has a TGA
  • the present invention also provides for a process for the preparation of N- Methylformamide solvate of dasatinib.
  • the process includes: a) treating dasatinib with N-Methylformamide; and b) isolating N-Methylformamide solvate of dasatinib.
  • Dasatinib in any previously known crystalline or amorphous form prepared by methods known in the art can be used as the starting material.
  • Step a) of the process involves adding dasatinib to N-Methylformamide or adding N-Methylformamide to dasatinib in optional order of succession at a suitable temperature of between 20°C to 50°C; preferably under stirring.
  • the addition may be performed at a temperature of between 20°C to 35°C.
  • N-Methylformamide may be used in an amount of 3 to 10 times the amount of dasatinib.
  • the resultant mixture is heated to a temperature of between about 50°C to 80°C for about 15 minutes to 3 hours. For example, it may be heated at about 60°C to 70°C.
  • Step b) of the process involves isolating N-Methylformamide solvate of dasatinib through common isolation techniques, such as one or more of washing, crystallization, precipitation, cooling, filtration, filtration under vacuum, decantation and centrifugation, or a combination thereof.
  • step b) involves filtration of the reaction mass obtained in step a) to remove foreign particulate matter or treated with activated charcoal to remove coloring and other related impurities.
  • the filtrate is maintained at about 10°C to 40°C for a time period of 2 hours to 24 hours to allow the N-Methylformamide solvate of dasatinib to crystallize.
  • the isolated crystalline N-Methylformamide solvate of dasatinib may be dried at 40°C to 60°C under vacuum for about 12 hours to 28 hours.
  • N-Methylformamide solvate of dasatinib may also be used for the preparation of other polymorphic forms or solvates of dasatinib.
  • the present invention also provides for a pharmaceutical composition that includes a therapeutically effective amount of N-Methylformamide solvate of dasatinib and one or more pharmaceutically acceptable excipient.
  • the present invention also provides for a method for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
  • the method includes administering to a mammal in need thereof a therapeutically effective amount of N- Methylformamide solvate of dasatinib.
  • Dasatinib (3.24 g) was charged in a round bottom flask. N-methyl formamide (20 ml) was added to it. The reaction mixture was heated at 70°C for 30 minutes and filtered. The filtrate was collected in a beaker and kept at a temperature of 20°C to 35°C overnight for crystallization. The solid was filtered and suck dried for 30 minutes. Solid was unloaded and dried under a vacuum at 55°C to 60°C for 24 hours to obtain the title compound.

Abstract

The present invention relates to the N-Methylformamide solvate of dasatinib a process for its preparation. Formula (I)

Description

iV-METHYLFORMAMIDE SOLVATE OF DASATINIB
Field of the Invention
The present invention relates to a N-Methylformamide solvate of dasatinib and a process for its preparation. Background of the Invention
Dasatinib monohydrate of Formula A, chemically described as N-(2-chloro-6- methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-l-piperazinyl]-2-methyl-4-pyrimidinyl]amino]- 5-thiazole carboxamide monohydrate, is a cyclic protein tyrosine kinase inhibitor.
Dasatinib monohydrate, marketed under the brand name Sprycel®, is indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib. Sprycel® is also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.
Figure imgf000002_0001
Formula A
U.S. Patent No. 6,596,746 provides a process for the preparation of dasatinib.
U.S. Patent No. 7,491,725 provides for the crystalline monohydrate, butanol solvate form, crystalline ethanol solvates and neat forms of dasatinib. It also provides a process for the preparation of crystalline monohydrate, butanol solvate form, crystalline ethanol solvate and neat form of dasatinib.
U.S. Publication No. 2009/0118297 provides for the anhydrous form, amorphous form, iso-propanol solvate, a n-propanol-dimethylsulfoxide ("DMSO") solvate, a DMSO solvate, a hemi tetrahydrofuran ("THF") solvate, a 2-methyl-tetrahydrofuran ("2-methyl THF") solvate, a hemi 1,4-dioxane solvate, a pyridine solvate, a toluene solvate, a methyl isobutyl ketone ("MIBK") solvate, a mono acetone solvate, an iso-propanol ("IPA")- DMSO solvate, a 2-butanol-DMSO solvate, an IPA-DMF solvate, an IPA solvate, an n- propanol-DMF solvate, an n-propanol solvate, a 2-butanol-DMF solvate, a 2-butanol solvate, an n-butanol-DMSO solvate, a DMF-water solvate, a DMF solvate, a methyl isopropyl ketone ("MIPK") solvate, a dimethoxyethane solvate, a cellosolve solvate, a methylacetate solvate, a methanol solvate, an ethylacetate solvate, a 2-pentanole solvate, a dimethyl carbonate solvate, an isopropylacetate solvate, an ethyleneglycol solvate, a dichloromethane solvate, a methylformate solvate, a tert-butanol solvate, a
dimethoxyethane solvate, a methylethylketone ("MEK") solvate, a monochlorobenzene solvate, a propylene glycol monoethyl ether ("PGME") solvate, a glycerol solvate, a cyclopentyl methyl ether solvate, a methyl tert butyl ether ("MTBE") solvate, an amylalcohol solvate, a glycerol formal solvate of dasatinib and processes for their preparation.
WO 2010/062715 discloses an isosorbide dimethyl ether solvate of dasatinib, a Ν,Ν'-dimethylethylene urea solvate of dasatinib, and a N,N'-dimethyl-N,N'-propylene urea solvate of dasatinib and processes for their preparation.
WO 2010/067374 discloses a dimethylformamide solvate, dimethyl sulfoxide solvate, toluene solvate, isopropyl acetate solvate, crystalline Form I of dasatinib characterized by their X-ray powder diffractogram and processes for their preparation. Polymorphism is defined as the ability of a substance to exist as two or more crystalline phases that have different arrangements and/or conformations of the molecule in the crystal lattice. Different polymorphs may differ in their physical properties, such as, melting point, solubility, X-ray diffraction patterns, and the like. Although these differences disappear once the compound is dissolved, they can appreciably influence the pharmaceutically relevant properties of the solid form, such as its handling properties, dissolution rate and stability. Such properties can significantly influence the processing, the shelf life, and the commercial acceptance of a polymorph. Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray Diffraction (XRD) powder as well as single crystal, DSC, IR, Solid state NMR, or Raman spectroscopy. The solvent medium and/or mode of isolation play a very important role in obtaining one polymorphic form over another.
The discovery of new solid state forms and solvates of a pharmaceutical compound provides a new opportunity to improve the pharmacokinetic properties of a pharmaceutical product. Therefore, there is a need for additional solid state forms of dasatinib.
The present inventors have now surprisingly found a N-Methylformamide solvate of dasatinib. The novel N-Methylformamide solvate of dasatinib of the present invention is suitable for preparing pharmaceutical compositions.
Summary of the Invention
In one general aspect, the present invention provides for N-Methylformamide solvate of dasatinib of Formula B.
Figure imgf000004_0001
Formula B
In another general aspect, the present invention provides for crystalline N- Methylformamide solvate of dasatinib characterized by an X-Ray Powder Diffractogram (XRPD) substantially as depicted in Figure 1.
In another general aspect, the present invention provides for crystalline N- Methylformamide solvate of dasatinib characterized by an X-ray Powder Diffractogram which includes interplanar distances at approximately 14.21 , 7.1 1 , 5.80, 4.74, and 3.65 A.
Embodiments of this aspect may include one or more of the following features. For example, the crystalline N-Methylformamide solvate of dasatinib may be further characterized by an X-ray Powder Diffractogram which includes interplanar distance at approximately 7.45, 4.83, 4.29, 3.82, 3.73 and 3.49 A.
The crystalline N-Methylformamide solvate of dasatinib may further be characterized by a DSC thermogram substantially as depicted in Figure 2. For example, the crystalline N-Methylformamide solvate of dasatinib may have characteristic DSC endothermic peaks at about 160°C and about 287°C.
The crystalline N-Methylformamide solvate of dasatinib may also be further characterized by a TGA substantially as depicted in Figure 3.
In yet another general aspect, the present invention provides for a process for the preparation of N-Methylformamide solvate of dasatinib. The process includes:
a) treating dasatinib with N-Methylformamide; and
b) isolating N-Methylformamide solvate of dasatinib.
Embodiments of this aspect may include one or more of the following features. For example, step a) is carried out at a temperature of 20°C to 50°C and the amount of N- Methylformamide is 3 to 10 times the amount of dasatinib.
In another general aspect, the present invention provides for the use of N- Methylformamide solvate of dasatinib for the preparation of other polymorphic forms or solvates of dasatinib.
In yet another general aspect, the present invention provides for a pharmaceutical composition which includes a therapeutically effective amount of N-Methylformamide solvate of dasatinib and one or more pharmaceutically acceptable excipients.
In another general aspect, the present invention provides for a method for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute
lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. The method includes administering to a mammal in need thereof a therapeutically effective amount of N-Methylformamide solvate of dasatinib.
Brief Description of the Drawings
Figure 1 and Figure la depicts X-Ray Powder Diffractogram (XRPD) of N- Methylformamide solvate of dasatinib and the associated values, respectively.
Figure 2 depicts Differential Scanning Calorimetry (DSC) thermogram of N- Methylformamide solvate of dasatinib. Figure 3 depicts Thermogravimetric Analysis (TGA) of N-Methylformamide solvate of dasatinib.
The XRPD was determined by using PANalytical X' Pert Pro X-Ray Powder Diffractometer in the range 0°C to 40°C 2Θ and under tube voltage and current of 45 Kv and 40 mA, respectively. Copper radiation of wavelength 1.54 angstrom and Xceletor detector was used.
The TGA was recorded on TA (Q500) (Rate of heating = 10°C/minute).
The DSC was recorded on Mettler Toledo (DSC 821) (Rate of heating = 10°C/minute).
Detailed Description of the Invention
The present invention provides for the N-Methylformamide solvate of dasatinib of Formula B
Figure imgf000006_0001
Formula B
The present invention may be in the form of crystalline N-Methylformamide solvate of dasatinib.
The crystalline N-Methylformamide solvate of dasatinib has an X-Ray Powder Diffractogram (XRPD) substantially as depicted in Figure 1 of the accompanied drawings. The crystalline N-Methylformamide solvate of dasatinib has an X-ray Powder Diffractogram which shows characteristic peaks expressed as interplanar distance at approximately 14.21, 7.11, 5.80, 4.74, and 3.65 A. The crystalline N- Methylformamide solvate of dasatinib may be further characterized by peaks expressed as interplanar distance at approximately 7.45, 4.83, 4.29, 3.82, 3.73 and 3.49 A. The crystalline N-Methylformamide solvate of dasatinib has a DSC thermogram substantially as depicted in Figure 2 of the accompanied drawings. The DSC thermogram shows characteristic endothermic peaks at about 160°C and about 287°C.
The crystalline N-Methylformamide solvate of dasatinib has a TGA
substantially as depicted in Figure 3 of the accompanied drawings. The TGA of the crystalline N-Methylformamide solvate of dasatinib shows a weight loss of about
10.6%.
The present invention also provides for a process for the preparation of N- Methylformamide solvate of dasatinib. The process includes: a) treating dasatinib with N-Methylformamide; and b) isolating N-Methylformamide solvate of dasatinib.
Dasatinib in any previously known crystalline or amorphous form prepared by methods known in the art can be used as the starting material.
Step a) of the process involves adding dasatinib to N-Methylformamide or adding N-Methylformamide to dasatinib in optional order of succession at a suitable temperature of between 20°C to 50°C; preferably under stirring. For example, the addition may be performed at a temperature of between 20°C to 35°C.
N-Methylformamide may be used in an amount of 3 to 10 times the amount of dasatinib.
After the completion of addition, the resultant mixture is heated to a temperature of between about 50°C to 80°C for about 15 minutes to 3 hours. For example, it may be heated at about 60°C to 70°C.
Step b) of the process involves isolating N-Methylformamide solvate of dasatinib through common isolation techniques, such as one or more of washing, crystallization, precipitation, cooling, filtration, filtration under vacuum, decantation and centrifugation, or a combination thereof.
For example, step b) involves filtration of the reaction mass obtained in step a) to remove foreign particulate matter or treated with activated charcoal to remove coloring and other related impurities. The filtrate is maintained at about 10°C to 40°C for a time period of 2 hours to 24 hours to allow the N-Methylformamide solvate of dasatinib to crystallize.
The isolated crystalline N-Methylformamide solvate of dasatinib may be dried at 40°C to 60°C under vacuum for about 12 hours to 28 hours.
The N-Methylformamide solvate of dasatinib may also be used for the preparation of other polymorphic forms or solvates of dasatinib.
The present invention also provides for a pharmaceutical composition that includes a therapeutically effective amount of N-Methylformamide solvate of dasatinib and one or more pharmaceutically acceptable excipient.
The present invention also provides for a method for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. The method includes administering to a mammal in need thereof a therapeutically effective amount of N- Methylformamide solvate of dasatinib.
While the present invention has been described in terms of its specific
embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLE
Preparation of N-Methylformamide Solvate of Dasatinib
Dasatinib (3.24 g) was charged in a round bottom flask. N-methyl formamide (20 ml) was added to it. The reaction mixture was heated at 70°C for 30 minutes and filtered. The filtrate was collected in a beaker and kept at a temperature of 20°C to 35°C overnight for crystallization. The solid was filtered and suck dried for 30 minutes. Solid was unloaded and dried under a vacuum at 55°C to 60°C for 24 hours to obtain the title compound.
Yield: 1.95 g

Claims

Claims: 1. N-Methylformarnide solvate of dasatinib of Formula B.
Figure imgf000009_0001
Formula B
2. Crystalline N-Methylformamide solvate of dasatinib characterized by an X-Ray Powder Diffractogram (XRPD) substantially as depicted in Figure 1.
3. Crystalline N-Methylformamide solvate of dasatinib characterized by an X-ray Powder Diffractogram comprising interplanar distance at approximately 14.21, 7.1 1 , 5.80, 4.74, and 3.65 A.
4. The crystalline N-Methylformamide solvate of dasatinib according to claim 3, further characterized by an X-ray Powder Diffractogram comprising interplanar distance at approximately 7.45, 4.83, 4.29, 3.82, 3.73 and 3.49 A.
5. The crystalline N-Methylformamide solvate of dasatinib according to claim 2, further characterized by a DSC thermogram substantially as depicted in Figure 2.
6. The crystalline N-Methylformamide solvate of dasatinib according to claim 2, further comprising a DSC having characteristic endothermic peaks at about 160°C and about 287°C.
7. The crystalline N-Methylformamide solvate of dasatinib according to claim 2, further characterized by a TGA substantially as depicted in Figure 3.
8. A process for the preparation of N-Methylformarnide solvate of dasatinib, the process comprising: c) treating dasatinib with N-Methylformarnide; and d) isolating N-Methylformamide solvate of dasatinib.
9. A process according to claim 8, wherein step a) is carried out at a temperature of 20°C to 50°C.
10. A process according to claim 8, wherein the amount of N-Methylformamide is 3 to 10 times the amount of dasatinib.
1 1. Use of N-Methylformamide solvate of dasatinib for the preparation of other polymorphic forms or solvates of dasatinib.
12. A pharmaceutical composition comprising a therapeutically effective amount of N- Methylformamide solvate of dasatinib and one or more pharmaceutically acceptable excipients.
13. A method for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy, the method comprising administering to a mammal in need thereof a therapeutically effective amount of N-Methylformamide solvate of dasatinib.
PCT/IB2011/053318 2010-07-30 2011-07-25 N-methylformamide solvate of dasatinib WO2012014149A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2806820A CA2806820A1 (en) 2010-07-30 2011-07-25 N-methylformamide solvate of dasatinib
AU2011284341A AU2011284341A1 (en) 2010-07-30 2011-07-25 N-Methylformamide solvate of dasatinib
EP11751946.2A EP2598147A1 (en) 2010-07-30 2011-07-25 N-methylformamide solvate of dasatinib

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1807DE2010 2010-07-30
IN1807/DEL/2010 2010-07-30

Publications (1)

Publication Number Publication Date
WO2012014149A1 true WO2012014149A1 (en) 2012-02-02

Family

ID=44545784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/053318 WO2012014149A1 (en) 2010-07-30 2011-07-25 N-methylformamide solvate of dasatinib

Country Status (4)

Country Link
EP (1) EP2598147A1 (en)
AU (1) AU2011284341A1 (en)
CA (1) CA2806820A1 (en)
WO (1) WO2012014149A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013186726A3 (en) * 2012-06-15 2014-02-20 Basf Se Multicomponent crystals comprising dasatinib and selected cocrystal formers
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
WO2017134615A1 (en) * 2016-02-03 2017-08-10 Dr. Reddy's Laboratories Limited Solid state forms of dasatinib and processes for their preparation
WO2018078392A1 (en) 2016-10-29 2018-05-03 Cipla Limited Polymorphs of dasatinib
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596746B1 (en) 1999-04-15 2003-07-22 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US20090118297A1 (en) 2007-10-23 2009-05-07 Ondrej Simo Polymorphs of dasatinib and process for preparation thereof
WO2010062715A2 (en) 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596746B1 (en) 1999-04-15 2003-07-22 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US20090118297A1 (en) 2007-10-23 2009-05-07 Ondrej Simo Polymorphs of dasatinib and process for preparation thereof
WO2010062715A2 (en) 2008-11-03 2010-06-03 Teva Pharmaceutical Industries Ltd. Polymorphs of dasatinib and process for preparation thereof
WO2010067374A2 (en) 2008-12-08 2010-06-17 Hetero Research Foundation Polymorphs of dasatinib

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2650524C2 (en) * 2012-06-15 2018-04-16 Басф Се Multicomponent crystals comprising dasatinib and selected cocrystal formers
JP2015525227A (en) * 2012-06-15 2015-09-03 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Multi-component crystals comprising dasatinib and a selected co-crystal former
US9340536B2 (en) 2012-06-15 2016-05-17 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
AU2013276138B2 (en) * 2012-06-15 2017-02-23 Basf Se Multicomponent crystals comprising Dasatinib and selected cocrystal formers
WO2013186726A3 (en) * 2012-06-15 2014-02-20 Basf Se Multicomponent crystals comprising dasatinib and selected cocrystal formers
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
US10464933B2 (en) 2016-02-03 2019-11-05 Dr. Reddy's Laboratories Limited Solid state forms of dasatinib and processes for their preparation
JP2019504090A (en) * 2016-02-03 2019-02-14 ドクター レディズ ラボラトリーズ リミテッド Solid state forms of dasatinib and their preparation process
WO2017134615A1 (en) * 2016-02-03 2017-08-10 Dr. Reddy's Laboratories Limited Solid state forms of dasatinib and processes for their preparation
WO2018078392A1 (en) 2016-10-29 2018-05-03 Cipla Limited Polymorphs of dasatinib
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
US11440908B2 (en) 2018-04-25 2022-09-13 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
US10869836B1 (en) 2019-05-17 2020-12-22 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10869837B1 (en) 2019-05-17 2020-12-22 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10874613B1 (en) 2019-05-17 2020-12-29 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10874614B1 (en) 2019-05-17 2020-12-29 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10894018B1 (en) 2019-05-17 2021-01-19 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10894017B1 (en) 2019-05-17 2021-01-19 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US11344500B2 (en) 2019-05-17 2022-05-31 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
US11833249B2 (en) 2019-05-17 2023-12-05 Xspray Pharma Ab Rapidly disintegrating solid oral dosage forms containing dasatinib

Also Published As

Publication number Publication date
AU2011284341A1 (en) 2013-02-21
CA2806820A1 (en) 2012-02-02
EP2598147A1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
JP6081763B2 (en) Dasatinib polymorph and its preparation process
US11149017B2 (en) Solid state forms of apalutamide
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
EP3180343A1 (en) Solid state forms of ibrutinib
US20090298947A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
EP3337485B1 (en) Crystalline forms of ibrutinib
EP2598147A1 (en) N-methylformamide solvate of dasatinib
US20090076272A1 (en) Polymorphs of eszopiclone malate
KR20190035680A (en) Polymorphism of binalinostet and its production method
WO2013065063A1 (en) Anhydrous form of dasatinib, process for its preparation and its use
WO2010144675A1 (en) Polymorphs of bendamustine hcl and processes for preparation thereof
US20150183767A1 (en) Novel polymorphs of azilsartan medoxomil
WO2017098391A1 (en) Process for the preparation of dasatinib
TW201829420A (en) New solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
CN111094241B (en) Crystal form of oxopyridine amide derivative and preparation method thereof
JP2011505416A (en) Process for the preparation of chemically and chirally pure solifenacin base and its salts
WO2014195977A2 (en) Novel polymorphs of vismodegib
WO2012125993A1 (en) Solid state forms of rilpivirine base, and rilipivirine salts
CA2811912A1 (en) Novel polymorphs of febuxostat
KR20200036867A (en) Polymorphs of dasatinib
CN116997331A (en) Quinolone compound in solid form and process for preparing same
WO2011114336A1 (en) Process for the isolation of ganciclovir intermediate
US20150291574A1 (en) Novel polymorphs of azilsartan
WO2015114479A1 (en) Crystalline forms of darapladib oxalate, adipate, succinate, phosphate, sulphate, fumaratetartrate, nitrate and borate
US20090062546A1 (en) Dolasetron trifluoroacetate, polymorphs of dolasetron trifluoroacetate and process for preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11751946

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2806820

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011751946

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011284341

Country of ref document: AU

Date of ref document: 20110725

Kind code of ref document: A